Stammdaten
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.
Unternehmen & Branche
| Name | Kairos Pharma, LTD. |
|---|---|
| Ticker | KAPA |
| CIK | 0001962011 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 12,3 Mio. USD |
| Beta | 1,98 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -5,447,000 | -0.30 | 6,540,000 | 6,341,000 | |
| 2025-09-30 | 10-Q | -1,398,000 | -0.07 | 8,066,000 | 7,664,000 | |
| 2025-06-30 | 10-Q | -1,422,000 | -0.08 | 6,673,000 | 5,997,000 | |
| 2025-03-31 | 10-Q | -1,262,000 | -0.08 | 7,937,000 | 7,132,000 | |
| 2024-12-31 | 10-K | -2,603,000 | -0.23 | 5,768,000 | 4,776,000 | |
| 2024-09-30 | 10-Q | -1,047,000 | -0.10 | 5,004,000 | 3,332,000 | |
| 2024-06-30 | 10-Q | -253,000 | -0.02 | -2,654,000 | ||
| 2024-03-31 | 10-Q | -323,000 | -0.03 | -2,401,000 | ||
| 2023-12-31 | 10-K | -1,812,000 | -0.17 | 965,000 | -2,078,000 | |
| 2023-12-31 | 10-Q | 1,812,000 | 965,000 | -2,078,000 | ||
| 2023-09-30 | 10-Q | -312,000 | -0.03 | -1,873,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.